MARK2 and gallbladder adenocarcinoma: Further studies to address the underlying mechanisms in which activation of the ERK and AKT pathways contributes to increased tumor aggressiveness and progression in gallbladder adenocarcinoma might offer the possibility to utilize serine/threonine kinase inhibitors as targeted therapeutics.